Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients.

Abstract

TLC G-65, a liposome-encapsulated gentamicin, was given intravenously twice weekly for 4 weeks to AIDS patients with Mycobacterium avium-M. intracellulare complex (MAC) bacteremia at 1.7 mg of gentamicin per kg of body weight per infusion (4 patients), 3.4 mg/kg (10 patients), and 5.1 mg/kg (7 patients). MAC colony counts in blood fell by 75% or more in all three groups (P < 0.005). Drug resistance did not emerge during the study period. Transient renal insufficiency developed in one patient; no other adverse effects were detected. Liposome-encapsulated gentamicin is a potential therapy for MAC infections in AIDS patients.

• Authors: S D Nightingale, S L Saletan, C E Swenson, A J Lawrence, D A Watson, F G Pilkiewicz, E G Silverman, S X Cal
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 37 Issue 9 Pg. 1869-72 (Sep 1993) ISSN: 0066-4804 [Print] United States
• PMID: 8239598 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Drug Carriers
• Gentamicins
• Liposomes

Topics

• Acquired Immunodeficiency Syndrome (complications)
• Adult
• Bacteremia (drug therapy, microbiology)
• Colony Count, Microbial
• Drug Carriers
• Female
• Gentamicins (administration & dosage, pharmacokinetics, therapeutic use)
• Humans
• Infusions, Intravenous
• Liposomes
• Male
• Mycobacterium avium Complex (drug effects, growth & development)
• Mycobacterium avium-intracellulare Infection (complications, drug therapy, microbiology)